Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.57 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.57 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17533564 | 0.88 | TSHR (0.41) | FOLH1NAALAD2GRM3TSHRPKM | |
| SCHEMBL17533562 | 0.81 | FOLH1 (0.36) | FOLH1NAALAD2GRM3SLC6A2SLC6A4 | |
| SCHEMBL17533519 | 0.80 | FOLH1 (0.56) | FOLH1NAALAD2GRM3TSHRPKM | |
| SCHEMBL17533535 | 0.77 | FOLH1 (0.65) | FOLH1NAALAD2GRM3 | |
| SCHEMBL16528808 | 0.74 | FOLH1 (1.00) | FOLH1NAALAD2GRM3 | |
| SCHEMBL16528703 | 0.74 | FOLH1 (1.00) | FOLH1NAALAD2GRM3 | |
| SCHEMBL383173 | 0.74 | FOLH1 (1.00) | FOLH1NAALAD2GRM3 | |
| SCHEMBL18280854 | 0.73 | TET2 (0.48) | FOLH1GRM3SLC6A2SLC6A4BLM | |
| SCHEMBL18280853 | 0.73 | TET2 (0.48) | FOLH1GRM3SLC6A2SLC6A4BLM | |
| SCHEMBL18280861 | 0.73 | TET2 (0.48) | FOLH1GRM3SLC6A2SLC6A4BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932664-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230115651-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2023-04-13 | — | — | US | disclosed |
| US-11325931-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325931-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | FOLH1 1/4885NAALAD2 111/4885GRM3 1812/4885 |
| US-20230115651-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | FOLH1 1/4885NAALAD2 89/4885GRM3 1678/4885 |
| US-11932664-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | FOLH1 1/4885NAALAD2 111/4885GRM3 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.